Long-term patient-reported neurocognitive outcomes in adult survivors of hematopoietic cell transplant
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
Survivors of hematopoietic cell transplant (HCT) are at risk for neurocognitive impairments, which can negatively affect quality of life. Given limited studies, we aimed to describe the neurocognitive outcomes in a cohort of long-term adult HCT survivors. Eligible survivors (age ≥21 years at HCT and alive ≥2 years following HCT) completed a 60-question survey of neurocognitive function and quality of life, which included the Neuro-Quality of Life Cognitive Function Short Form (Neuro-QoL) and the Childhood Cancer Survivor Study Neurocognitive Questionnaire (NCQ). Analyses of risk factors included univariate comparisons and multivariable logistic regression. Survivors (n = 1861, 47.7% female, 65.6% allogeneic HCT) were surveyed at a median age of 64.2 years (interquartile range [IQR], 56.8-70.5) and a median 12.0 years (IQR, 6.0-21.0) from HCT. Survivors reported average Neuro-QoL scores (50.0 allogeneic; 49.2 autologous survivors) compared with an expected mean of 50 in the general population. On the NCQ, 17.4% to 31.2% of survivors reported impairments (Z-score >1.28) in task efficiency, memory, emotional regulation, or organization, compared with an expected 10% in the general population (all P < .01). In multivariable regression analyses, impaired Neuro-QoL (T-score <40) was independently associated with hearing issues (odds ratio [OR], 2.13; 95% confidence interval [CI], 1.46-3.10) and sleep impairment (OR, 4.41; 95% CI, 2.80-6.94) among allogeneic survivors, with comparable associations in autologous survivors. Overall, long-term adult HCT survivors reported average cognitive quality of life compared with the general population. Subsets of survivors with hearing issues and sleep impairments were more likely to report lower quality of life and impaired neurocognitive function, which may facilitate targeted monitoring or interventions following HCT.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
---|---|
Enthalten in: |
Blood advances - 6(2022), 14 vom: 26. Juli, Seite 4347-4356 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wu, Natalie L [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 27.07.2022 Date Revised 04.08.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.1182/bloodadvances.2021006672 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM34107165X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM34107165X | ||
003 | DE-627 | ||
005 | 20231226010928.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1182/bloodadvances.2021006672 |2 doi | |
028 | 5 | 2 | |a pubmed24n1136.xml |
035 | |a (DE-627)NLM34107165X | ||
035 | |a (NLM)35584396 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wu, Natalie L |e verfasserin |4 aut | |
245 | 1 | 0 | |a Long-term patient-reported neurocognitive outcomes in adult survivors of hematopoietic cell transplant |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.07.2022 | ||
500 | |a Date Revised 04.08.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
520 | |a Survivors of hematopoietic cell transplant (HCT) are at risk for neurocognitive impairments, which can negatively affect quality of life. Given limited studies, we aimed to describe the neurocognitive outcomes in a cohort of long-term adult HCT survivors. Eligible survivors (age ≥21 years at HCT and alive ≥2 years following HCT) completed a 60-question survey of neurocognitive function and quality of life, which included the Neuro-Quality of Life Cognitive Function Short Form (Neuro-QoL) and the Childhood Cancer Survivor Study Neurocognitive Questionnaire (NCQ). Analyses of risk factors included univariate comparisons and multivariable logistic regression. Survivors (n = 1861, 47.7% female, 65.6% allogeneic HCT) were surveyed at a median age of 64.2 years (interquartile range [IQR], 56.8-70.5) and a median 12.0 years (IQR, 6.0-21.0) from HCT. Survivors reported average Neuro-QoL scores (50.0 allogeneic; 49.2 autologous survivors) compared with an expected mean of 50 in the general population. On the NCQ, 17.4% to 31.2% of survivors reported impairments (Z-score >1.28) in task efficiency, memory, emotional regulation, or organization, compared with an expected 10% in the general population (all P < .01). In multivariable regression analyses, impaired Neuro-QoL (T-score <40) was independently associated with hearing issues (odds ratio [OR], 2.13; 95% confidence interval [CI], 1.46-3.10) and sleep impairment (OR, 4.41; 95% CI, 2.80-6.94) among allogeneic survivors, with comparable associations in autologous survivors. Overall, long-term adult HCT survivors reported average cognitive quality of life compared with the general population. Subsets of survivors with hearing issues and sleep impairments were more likely to report lower quality of life and impaired neurocognitive function, which may facilitate targeted monitoring or interventions following HCT | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
700 | 1 | |a Phipps, Amanda I |e verfasserin |4 aut | |
700 | 1 | |a Krull, Kevin R |e verfasserin |4 aut | |
700 | 1 | |a Syrjala, Karen L |e verfasserin |4 aut | |
700 | 1 | |a Carpenter, Paul A |e verfasserin |4 aut | |
700 | 1 | |a Connelly-Smith, Laura S |e verfasserin |4 aut | |
700 | 1 | |a Flowers, Mary E |e verfasserin |4 aut | |
700 | 1 | |a Krakow, Elizabeth F |e verfasserin |4 aut | |
700 | 1 | |a Ueda Oshima, Masumi |e verfasserin |4 aut | |
700 | 1 | |a Lee, Stephanie J |e verfasserin |4 aut | |
700 | 1 | |a Chow, Eric J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 6(2022), 14 vom: 26. Juli, Seite 4347-4356 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
773 | 1 | 8 | |g volume:6 |g year:2022 |g number:14 |g day:26 |g month:07 |g pages:4347-4356 |
856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2021006672 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 6 |j 2022 |e 14 |b 26 |c 07 |h 4347-4356 |